Company: PTHS
Filing Date: 2025-11-14
Form Type: PRE 14A
Source: 0001753926-25-001803
Chunk: 14

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-11-14
Form: PRE 14A
Chunk 14
---
 and as our Chief Executive Officer since July 2025. Prior to joining LNHC, Mr. Plesha served as the President and Chief Commercial Officer at BioDelivery Sciences (BDSI), a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions, from January 2018 until it was acquired by Collegium Pharmaceutical in 2022. Mr. Plesha joined BioDelivery Sciences in August 2015 as Senior Vice President, Sales, and assumed the additional responsibility of leading the marketing department in December 2015. He previously served as Senior Vice President of Gastrointestinal Sales at Salix Pharmaceuticals. Before Salix, Mr. Plesha was a Regional Sales Manager for Oclassen Dermatologics, a division of Watson Laboratories, and in commercial roles of increasing responsibility at Solvay Pharmaceuticals. Mr. Plesha received a Bachelor of Arts in Pre-Medical Studies from DePauw University. He was selected to serve as the Company’s Chief Executive Officer, President and Director due to his previous leadership of LNHC and extensive experience in sales and sales management in the pharmaceutical and medical industries.

Vote Required and Recommendation

Our Articles of Incorporation do not authorize
cumulative voting. Nevada law and our Bylaws provide that directors are to be elected by a plurality of the votes cast by the holders
of shares of Common Stock in person, by remote communication, if applicable, or represented by proxy at the Annual Meeting and
entitled to vote generally on the election of directors. This means that the seven (7) candidates receiving the highest number
of affirmative votes at the Annual Meeting will be elected as directors. Only shares that are voted in favor of a particular nominee
will be counted toward that nominee’s achievement of a plurality. Shares present at the Annual Meeting that are not voted
for a particular nominee or shares present by proxy where the shareholder properly withheld authority to vote for such nominee
will not be counted toward that nominee’s achievement of a plurality.

Votes withheld will be counted for purposes of determining the presence or absence of a quorum but will not be counted as votes cast for any particular nominee. Broker non-votes are not entitled to vote on Proposal No. 1, and broker non-votes, if any, will be counted for purposes of determining the presence or absence of a quorum but will not be counted for purposes of determining votes cash for any particular nominee.

At the Annual Meeting, a vote will be taken on a proposal to approve the election of the seven (7